A Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplant.

This study is ongoing, but not recruiting participants.

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00140907

Purpose

A study to determine the renal protective effect (measured as an incidence of chronic allograft nephropathy)of losartan in patients after renal transplant.

Condition	Intervention	Phase
Renal Disorder	Drug: MK0954, losartan potassium/Duration of Treatment: 2 years Drug: Comparator: placebo / Duration of Treatment: 2 years	Phase IV

MedlinePlus related topics: Kidney Transplantation

Drug Information available for: Losartan Losartan potassium Potassium chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Extension Study Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplants

Further study details as provided by Merck:

Primary Outcome Measures:

Number of patients who experience histological lesions of chronic allograft nephropathy

Secondary Outcome Measures:

Cardiovascular morbidity and mortality, plasma levels of creatinine, proteinuria, safety and tolerability

Estimated Enrollment:	420
Study Start Date:	April 2000

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males or females at least 18 years of age who have undergone a renal transplant.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00140907

Locations

Spain
Merck Sharp & Dohme De Espana, S.A.E.
Madrid, Spain, 28027

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Study ID Numbers:	2005_053
Study First Received:	August 30, 2005
Last Updated:	October 25, 2005
ClinicalTrials.gov Identifier:	NCT00140907
Health Authority:	Spain: Ministry of Health

Study placed in the following topic categories:

Losartan
Urologic Diseases
Kidney Diseases
Angiotensin II

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Cardiovascular Agents

Anti-Arrhythmia Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 13, 2009